# A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Source: https://onco.cc/trials/nct05514054/  
OnCo record `nct05514054` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer is a phase 3 interventional study registered as NCT05514054 by Eli Lilly and Company, with 8000 participants enrolled, started 2022-10-04 and due to reach its primary completion in 2027-10. Interventions recorded: Imlunestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05514054
- Phase: 3
- Setting: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
- Sponsor: Eli Lilly and Company
- Enrolled: 8000

## Sources

- ClinicalTrials.gov NCT05514054: https://clinicaltrials.gov/study/NCT05514054

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Exemestane](https://onco.cc/drugs/exemestane/), [Imlunestrant](https://onco.cc/drugs/imlunestrant/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct05514054.json